CL2021000207A1 - Nuevas proteínas de fusión específicas para cd137 y pd-l1 - Google Patents

Nuevas proteínas de fusión específicas para cd137 y pd-l1

Info

Publication number
CL2021000207A1
CL2021000207A1 CL2021000207A CL2021000207A CL2021000207A1 CL 2021000207 A1 CL2021000207 A1 CL 2021000207A1 CL 2021000207 A CL2021000207 A CL 2021000207A CL 2021000207 A CL2021000207 A CL 2021000207A CL 2021000207 A1 CL2021000207 A1 CL 2021000207A1
Authority
CL
Chile
Prior art keywords
fusion proteins
compositions
nucleic acid
acid molecules
methods
Prior art date
Application number
CL2021000207A
Other languages
English (en)
Spanish (es)
Inventor
Marlon Hinner
Christine Rothe
Shane Olwill
Marina Pavlidou
Lucia Pattarini
Alix Scholer-Dahirel
Aiba Rachida Bel
Janet Peper
Original Assignee
Servier Lab
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Pieris Pharmaceuticals Gmbh filed Critical Servier Lab
Publication of CL2021000207A1 publication Critical patent/CL2021000207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2021000207A 2018-07-31 2021-01-26 Nuevas proteínas de fusión específicas para cd137 y pd-l1 CL2021000207A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18204548 2018-11-06

Publications (1)

Publication Number Publication Date
CL2021000207A1 true CL2021000207A1 (es) 2021-08-13

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000207A CL2021000207A1 (es) 2018-07-31 2021-01-26 Nuevas proteínas de fusión específicas para cd137 y pd-l1

Country Status (28)

Country Link
US (1) US20210363257A1 (https=)
EP (2) EP4249064A3 (https=)
JP (1) JP7482488B2 (https=)
KR (1) KR20210040103A (https=)
CN (1) CN112789292A (https=)
AU (1) AU2019315703A1 (https=)
BR (1) BR112020025263A2 (https=)
CA (1) CA3100119A1 (https=)
CL (1) CL2021000207A1 (https=)
CY (1) CY1126148T1 (https=)
DK (1) DK3830120T5 (https=)
ES (1) ES2948717T3 (https=)
FI (1) FI3830120T3 (https=)
HR (1) HRP20230590T2 (https=)
HU (1) HUE062320T2 (https=)
IL (1) IL279541A (https=)
LT (1) LT3830120T (https=)
MD (1) MD3830120T3 (https=)
MX (1) MX2021000401A (https=)
MY (1) MY200710A (https=)
PH (1) PH12021550001A1 (https=)
PL (1) PL3830120T3 (https=)
RS (1) RS64343B9 (https=)
SG (1) SG11202100989UA (https=)
SI (1) SI3830120T1 (https=)
TW (1) TWI837156B (https=)
WO (1) WO2020025659A1 (https=)
ZA (1) ZA202100125B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB
WO2022082005A1 (en) * 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
CA3203718A1 (en) * 2021-01-08 2022-07-14 Jiawang Liu Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
KR20250071257A (ko) * 2022-09-21 2025-05-21 씨젠 인크. Cd137 및 cd228에 특이적인 신규한 융합 단백질
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
KR20170138574A (ko) * 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
KR102734408B1 (ko) * 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
JP6432121B2 (ja) * 2016-03-04 2018-12-05 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド Ｐｄｌ−１抗体、その医薬組成物及びその使用
CN108350082B (zh) 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR102678252B1 (ko) * 2017-09-01 2024-06-26 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Also Published As

Publication number Publication date
MD3830120T3 (ro) 2023-11-30
BR112020025263A2 (pt) 2021-03-09
CA3100119A1 (en) 2020-02-06
HUE062320T2 (hu) 2023-10-28
IL279541A (en) 2021-01-31
HRP20230590T2 (hr) 2024-02-16
KR20210040103A (ko) 2021-04-12
EP3830120B1 (en) 2023-05-24
RS64343B9 (sr) 2023-11-30
HRP20230590T1 (hr) 2023-09-15
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
CY1126148T1 (el) 2023-11-15
EP3830120A1 (en) 2021-06-09
US20210363257A1 (en) 2021-11-25
EP3830120B9 (en) 2023-08-30
MD3830120T2 (ro) 2023-08-31
WO2020025659A1 (en) 2020-02-06
PH12021550001A1 (en) 2021-09-27
LT3830120T (lt) 2023-07-10
FI3830120T3 (fi) 2023-06-13
DK3830120T3 (da) 2023-06-26
MY200710A (en) 2024-01-12
EP4249064A3 (en) 2023-12-06
JP2021533203A (ja) 2021-12-02
TWI837156B (zh) 2024-04-01
DK3830120T5 (da) 2024-08-19
CN112789292A (zh) 2021-05-11
SI3830120T1 (sl) 2023-10-30
AU2019315703A1 (en) 2020-12-10
EP4249064A2 (en) 2023-09-27
TW202019967A (zh) 2020-06-01
ES2948717T3 (es) 2023-09-18
PL3830120T3 (pl) 2023-10-09
MX2021000401A (es) 2021-03-25
ZA202100125B (en) 2023-06-28
JP7482488B2 (ja) 2024-05-14

Similar Documents

Publication Publication Date Title
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX390894B (es) Polipéptido de fusión anti-cáncer.
EP4378962A3 (en) Anti-cancer fusion polypeptide
ZA202104287B (en) Novel fusion proteins specific for cd137 and gpc3
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
HK1254450A1 (zh) 对lag-3和pd-1特异性的新型融合多肽
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
BR112017026292A2 (pt) muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico
BR112014019459A8 (pt) Proteínas de ligação à cdim e usos das mesmas
ECSP15025845A (es) Anticuerpos anti-ceacam5 y usos de éstos
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2025006169A (es) Inmunoglobulinas de enlace a mmp13
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
AR115878A1 (es) Proteínas de fusión específicas para cd137 y pd-l1
BR112017020008A8 (pt) Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele
AR127728A1 (es) Nueva proteína de fusión específica para ox40 y pd-l1